DiBiCol is a diagnostic test that differentiates between ulcerative colitis (UC) and Crohn’s disease (CD), the two major forms of inflammatory bowel disease (IBD). At the same time the test either confirms (IBD), or points to the less severe condition Irritable Bowel Syndrome (IBS).
As from June 27, 2012 the DiBiCol Sampling Kit is CE marked.
A unique method to classify IBD
DiBiCol enables a quick and accurate diagnosis of Inflammatory Bowel Diseases (IBD). It is a PCR-based method that monitors seven proprietary biomarkers specific for UC or CD from a single colonic biopsy. By applying a specially designed algorithm, a diagnosis can be made with a high degree of certainty.
Challenges in diagnosing IBD
Today there are about 3 million people in the EU and US that suffer from IBD. Using traditional methods it has been difficult to discriminate between UC and CD, why 10-15 percent never get a complete diagnosis, but are said to have an unclassified form, so called IBDU. In some cases a previously established diagnosis is changed during the disease history of a patient.
DiBiCol provides objective test results, and allows treating physicians to prescribe the most appropriate treatment options on an individual patient basis.
Verified in Clinical studies and routine clinical use
DiBiCol has been verified in three clinical studies including more than 300 patients and the results were published in Gastroenterology, June 2008. In 2009 DiBiCol received market approval in Sweden and has since been used in clinical routine practice at a large number of clinics, European Gastroenterology & Hepatology Review, Spring 2012. The good performance of DiBiCol was confirmed in a study conducted by Janczewska et al. Scandinavian Journal of Gastroenterology, February 2012, click here for abstract.